A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This open-label, international multi-center extension study WA18695 was designed to assess
the long term safety of tocilizumab in patients who had moderate to severe active rheumatoid
arthritis (RA). Patients enrolled in the WA18695 study had previously received treatment in
the 24-week, placebo-controlled, Phase III Study WA17822. Eligible patients were assigned to
treatment with 8 mg/kg tocilizumab every 4 weeks for a maximum of 5 years.